An ASO therapy reduced tau levels in patients with AlzheimersDisease in a phase 1b trial, but whether this translates to clinical improvement remains to be seen. Read the News and Views from Peter Ljubenkov & Gil Rabinovici RabLab_UCSF UCSFMedicine
P.A.L. receives research search support from the National Institute on Aging of the US National Institutes of Health and from the Alzheimer’s Association Part the Cloud Partnership. He is the FDA investigational new drug sponsor for a clinical trial of a drug supplied by Biohaven. He has served as a clinical site primary investigator for trials sponsored by Woolsey, Alector, Transposon and AbbVie.
He also currently serves as a clinical site sub-investigator for clinical trials sponsored by Lilly, Eisai and Biogen. G.D.R. receives research support from the US National Institutes of Health, the Alzheimer’s Association, the American College of Radiology, the Rainwater Charitable Foundation and the Alliance for Therapies in Neuroscience. He has served as a paid scientific advisor to Alector, Eli Lilly, GE Healthcare, Genentech, Johnson & Johnson Merck, and Roche.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man - Nature MedicineCase report of an individual heterozygous for a rare RELN-COLBOS variant that confers resilience, via a gain-of-function mechanism, to Alzheimer’s disease. ytquiroz DrJoeArboleda diegosflab
Weiterlesen »
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice - Nature MedicineIndividuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
Weiterlesen »
How to turn evidence into policy in resource-limited settings - Nature MedicineHow to turn evidence into policy in resource-limited settings. World View from Patti Gravitt, NCIGlobalHealth, as part of our series Rethinking Evidence in Medicine.
Weiterlesen »
The nature of an ultra-faint galaxy in the cosmic dark ages seen with JWST - NatureThe JWST, with the aid of gravitational lensing, confirms the extreme distance of an ultra-faint galaxy at a redshift of 9.79, showing it to have a luminosity typical of the sources responsible for cosmic reionization and highly compact and complex morphology.
Weiterlesen »
Erdogan did remarkably well in quake-hit areas, silencing his criticsBoth President Erdogan and AK Party’s victory in the disaster-hit areas is a testament to Erdogan’s popularity and shows that most Turkish earthquake survivors trust his leadership more than the opposition’s promises.
Weiterlesen »
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results - Nature MedicineIn updated results from a phase 1 trial of GD2-specific CAR-NKT cells in patients with neuroblastoma, no dose-limiting toxicities were observed across multiple dose levels; the maximum tolerated dose was not reached; and there was evidence of anti-tumor activity.
Weiterlesen »